According to Tufts Center for the Study of Drug Development, the average time to build and release a clinical study database is more than 73 days and the average time to lock data at the end of a trial is nearly 39 days.
In 2017, Vertex Pharmaceuticals addressed this issue head-on by setting aggressive internal targets. The company has since reduced database build and release times from 12-14 weeks to six to eight, and data lock times from 22 days to just 15.
On 27/02/2020 mesoblast announced in their half year results.
"The Phase 3 trial of REVASCOR® for advanced chronic heart failure surpassed the number of primary
endpoint events required for trial completion. "
Using the 12-14 weeks time frame we are about due to receive data.
Hold on for the ride.
Glta
Fishywoo
- Forums
- ASX - By Stock
- REVASCOR® for advanced chronic heart failure
According to Tufts Center for the Study of Drug Development, the...
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
93.0¢ |
Change
0.015(1.64%) |
Mkt cap ! $1.061B |
Open | High | Low | Value | Volume |
92.5¢ | 95.0¢ | 89.0¢ | $7.902M | 8.522M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2945 | 92.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
93.0¢ | 40422 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2945 | 0.925 |
21 | 78815 | 0.920 |
7 | 186474 | 0.915 |
5 | 59510 | 0.910 |
4 | 173134 | 0.905 |
Price($) | Vol. | No. |
---|---|---|
0.930 | 40422 | 4 |
0.935 | 55000 | 2 |
0.940 | 61500 | 3 |
0.945 | 68142 | 7 |
0.950 | 512886 | 20 |
Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
Last
93.0¢ |
  |
Change
0.015 ( 2.54 %) |
|||
Open | High | Low | Volume | ||
92.0¢ | 95.0¢ | 89.5¢ | 2254102 | ||
Last updated 15.59pm 26/04/2024 ? |
Featured News
MSB (ASX) Chart |